Mounjaro (tirzepatide) continues its market dominance with Eli Lilly reporting a 110% revenue surge in Q4 2025 results. While new studies highlight breakthrough benefits for liver health (MASH) and heart failure, UK regulators have officially banned illegal social media promotions. Experts warn of rapid weight regain if the medication is stopped.